Hitting a moving target: Glioma stem cells demand new approaches in glioblastoma therapy

Drew A. Spencer, Brenda M. Auffinger, Jason P. Murphy, Megan E. Muroski, Jian Qiao, Yureve Gorind, Maciej S. Lesniak

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Background: Glioblastoma multiforme (GBM) continues to devastate patients and outfox investigators and clinicians despite the preponderance of research directed at its biology, pathogenesis and therapeutic advances. GBM routinely outlasts multidisciplinary treatment protocols, almost inevitably recurring in a yet more aggressive and resistant form with distinct genetic differences from the original tumor. Attempts to glean further insight into GBM point increasingly toward a subpopulation of cells with a stem-like phenotype. These cancer stem cells, similar to those now described in a variety of malignancies, are capable of tumorigenesis from a population of susceptible cells. Conclusions: Glioma stem cells have thus become a prevalent focus in GBM research for their presumed role in development, maintenance and recurrence of tumors. Glioma stem cells infiltrate the white matter surrounding tumors and often evade resection. They are uniquely suited both biochemically and environmentally to resist the best therapy currently available, intrinsically and efficiently resistant to standard chemo- and radiotherapy. These stem cells create an extremely heterogenous tumor that to date has had an answer for every therapeutic question, with continued dismal patient survival. Targeting this population of glioma stem cells may hold the long-awaited key to durable therapeutic efficacy in GBM.

Original languageEnglish (US)
Pages (from-to)236-254
Number of pages19
JournalCurrent Cancer Drug Targets
Volume17
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Glioblastoma
Glioma
Stem Cells
Neoplasms
Therapeutics
Neoplastic Stem Cells
Clinical Protocols
Research
Population
Carcinogenesis
Radiotherapy
Maintenance
Research Personnel
Phenotype
Recurrence
Drug Therapy
Survival

Keywords

  • Chemotherapy
  • Drug targets
  • Glioblastoma multiforme
  • Glioma stem cells
  • Niches
  • Recurrence
  • Resistance

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Cancer Research

Cite this

Spencer, D. A., Auffinger, B. M., Murphy, J. P., Muroski, M. E., Qiao, J., Gorind, Y., & Lesniak, M. S. (2017). Hitting a moving target: Glioma stem cells demand new approaches in glioblastoma therapy. Current Cancer Drug Targets, 17(3), 236-254. https://doi.org/10.2174/1568009616666161215161924

Hitting a moving target : Glioma stem cells demand new approaches in glioblastoma therapy. / Spencer, Drew A.; Auffinger, Brenda M.; Murphy, Jason P.; Muroski, Megan E.; Qiao, Jian; Gorind, Yureve; Lesniak, Maciej S.

In: Current Cancer Drug Targets, Vol. 17, No. 3, 01.03.2017, p. 236-254.

Research output: Contribution to journalReview article

Spencer, DA, Auffinger, BM, Murphy, JP, Muroski, ME, Qiao, J, Gorind, Y & Lesniak, MS 2017, 'Hitting a moving target: Glioma stem cells demand new approaches in glioblastoma therapy', Current Cancer Drug Targets, vol. 17, no. 3, pp. 236-254. https://doi.org/10.2174/1568009616666161215161924
Spencer, Drew A. ; Auffinger, Brenda M. ; Murphy, Jason P. ; Muroski, Megan E. ; Qiao, Jian ; Gorind, Yureve ; Lesniak, Maciej S. / Hitting a moving target : Glioma stem cells demand new approaches in glioblastoma therapy. In: Current Cancer Drug Targets. 2017 ; Vol. 17, No. 3. pp. 236-254.
@article{facd0002f8cf4c7bb04296000a599aba,
title = "Hitting a moving target: Glioma stem cells demand new approaches in glioblastoma therapy",
abstract = "Background: Glioblastoma multiforme (GBM) continues to devastate patients and outfox investigators and clinicians despite the preponderance of research directed at its biology, pathogenesis and therapeutic advances. GBM routinely outlasts multidisciplinary treatment protocols, almost inevitably recurring in a yet more aggressive and resistant form with distinct genetic differences from the original tumor. Attempts to glean further insight into GBM point increasingly toward a subpopulation of cells with a stem-like phenotype. These cancer stem cells, similar to those now described in a variety of malignancies, are capable of tumorigenesis from a population of susceptible cells. Conclusions: Glioma stem cells have thus become a prevalent focus in GBM research for their presumed role in development, maintenance and recurrence of tumors. Glioma stem cells infiltrate the white matter surrounding tumors and often evade resection. They are uniquely suited both biochemically and environmentally to resist the best therapy currently available, intrinsically and efficiently resistant to standard chemo- and radiotherapy. These stem cells create an extremely heterogenous tumor that to date has had an answer for every therapeutic question, with continued dismal patient survival. Targeting this population of glioma stem cells may hold the long-awaited key to durable therapeutic efficacy in GBM.",
keywords = "Chemotherapy, Drug targets, Glioblastoma multiforme, Glioma stem cells, Niches, Recurrence, Resistance",
author = "Spencer, {Drew A.} and Auffinger, {Brenda M.} and Murphy, {Jason P.} and Muroski, {Megan E.} and Jian Qiao and Yureve Gorind and Lesniak, {Maciej S.}",
year = "2017",
month = "3",
day = "1",
doi = "10.2174/1568009616666161215161924",
language = "English (US)",
volume = "17",
pages = "236--254",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Hitting a moving target

T2 - Glioma stem cells demand new approaches in glioblastoma therapy

AU - Spencer, Drew A.

AU - Auffinger, Brenda M.

AU - Murphy, Jason P.

AU - Muroski, Megan E.

AU - Qiao, Jian

AU - Gorind, Yureve

AU - Lesniak, Maciej S.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Background: Glioblastoma multiforme (GBM) continues to devastate patients and outfox investigators and clinicians despite the preponderance of research directed at its biology, pathogenesis and therapeutic advances. GBM routinely outlasts multidisciplinary treatment protocols, almost inevitably recurring in a yet more aggressive and resistant form with distinct genetic differences from the original tumor. Attempts to glean further insight into GBM point increasingly toward a subpopulation of cells with a stem-like phenotype. These cancer stem cells, similar to those now described in a variety of malignancies, are capable of tumorigenesis from a population of susceptible cells. Conclusions: Glioma stem cells have thus become a prevalent focus in GBM research for their presumed role in development, maintenance and recurrence of tumors. Glioma stem cells infiltrate the white matter surrounding tumors and often evade resection. They are uniquely suited both biochemically and environmentally to resist the best therapy currently available, intrinsically and efficiently resistant to standard chemo- and radiotherapy. These stem cells create an extremely heterogenous tumor that to date has had an answer for every therapeutic question, with continued dismal patient survival. Targeting this population of glioma stem cells may hold the long-awaited key to durable therapeutic efficacy in GBM.

AB - Background: Glioblastoma multiforme (GBM) continues to devastate patients and outfox investigators and clinicians despite the preponderance of research directed at its biology, pathogenesis and therapeutic advances. GBM routinely outlasts multidisciplinary treatment protocols, almost inevitably recurring in a yet more aggressive and resistant form with distinct genetic differences from the original tumor. Attempts to glean further insight into GBM point increasingly toward a subpopulation of cells with a stem-like phenotype. These cancer stem cells, similar to those now described in a variety of malignancies, are capable of tumorigenesis from a population of susceptible cells. Conclusions: Glioma stem cells have thus become a prevalent focus in GBM research for their presumed role in development, maintenance and recurrence of tumors. Glioma stem cells infiltrate the white matter surrounding tumors and often evade resection. They are uniquely suited both biochemically and environmentally to resist the best therapy currently available, intrinsically and efficiently resistant to standard chemo- and radiotherapy. These stem cells create an extremely heterogenous tumor that to date has had an answer for every therapeutic question, with continued dismal patient survival. Targeting this population of glioma stem cells may hold the long-awaited key to durable therapeutic efficacy in GBM.

KW - Chemotherapy

KW - Drug targets

KW - Glioblastoma multiforme

KW - Glioma stem cells

KW - Niches

KW - Recurrence

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=85013928289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013928289&partnerID=8YFLogxK

U2 - 10.2174/1568009616666161215161924

DO - 10.2174/1568009616666161215161924

M3 - Review article

C2 - 27993114

AN - SCOPUS:85013928289

VL - 17

SP - 236

EP - 254

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 3

ER -